<p><em>经验丰富的肿瘤学和生命科学高管将领导财务战略并支持下一阶段的增长</em></p>
<p>要查看此发布的 PDF，请点击这里</p>
<p>, /PRNewswire/ -- Delphi Diagnostics 今天宣布任命 Eric Lindquist 为首席财务官，任职于 2026 年 4 月 1 日生效。Lindquist 先生在制药和诊断公司拥有数十年的领导经验，在商业化、企业战略和资本形成方面有着良好的业绩记录。他在公司推进内分泌活性指数®（EAI™）测试以改善乳腺癌治疗决策的关键时刻加入 Delphi。</p>
<p>最近，Lindquist 先生担任 InnoSIGN 的首席执行官，领导了公司的战略转型并完成了多轮融资。在加入 InnoSIGN 之前，他是 Celcuity 的首席商务和商业官，负责收购 gedatolisib，并帮助将该项目推进至 III 期乳腺癌临床试验。</p>
<p>在职业生涯早期，Lindquist 先生在 Natera 担任高级领导职务，发挥了关键作用，推出了 Signatera，这是一种针对每位患者独特癌症特征的个性化分子残留病检测。他还通过业务发展和战略合作伙伴关系的角色，帮助罗氏确立了在伴随诊断领域的领导地位。</p>
<p>“Eric 在肿瘤学、诊断和战略金融交汇处拥有深厚的专业知识，” Delphi Diagnostics 首席执行官 Winz Casagrande 说。“他在引导公司通过关键增长里程碑方面的经验，将对我们扩大 EAI 的可及性并继续构建下一代乳腺癌诊断以指导个性化治疗至关重要。”</p>
<p>“Delphi Diagnostics 在改变乳腺癌治疗决策方面具有独特的优势，” Lindquist 先生说。“公司基于生物学的 EAI 方法有潜力为复杂的临床决策带来更大的清晰度。我期待与团队合作，执行其战略并推动长期价值。”</p>
<p>Lindquist 先生获得明尼苏达大学的遗传学和细胞生物学学士学位，以及 Capella 大学的 MBA 学位。</p>
<p><strong>关于 EAI</strong> Delphi Diagnostics 的内分泌活性指数®（EAI™）测试可以为 II-III 期 HR+ HER2- 乳腺癌的预后和预测剂量强度紫杉烷化疗的益处提供可操作的信息。EAI 测量乳腺肿瘤的内分泌活性，作为预后使用时，指数分数根据分子亚型基因（RNA4）和肿瘤大小及区域淋巴结受累等临床因素进行基线预后调整。EAI 测试在多项研究中已被证明是 II-III 期乳腺癌患者长期结果的一致预后指标，独立于其他预后测试，并且能够预测对剂量密集化疗的反应。</p>
<p><strong>关于 Delphi Diagnostics</strong> Delphi Diagnostics Inc. 是一家总部位于德克萨斯州的公司，专注于推进临床有效的乳腺癌治疗预后和预测测试。Delphi Diagnostics, Inc. 拥有来自德克萨斯大学 MD 安德森癌症中心的独家许可，以商业化内分泌活性指数，这项技术由 W. Fraser Symmans 博士的实验室开发。内分泌活性指数（EAI）测试测量 II-III 期 HR+HER2- 乳腺癌的内分泌活性。Delphi 的愿景是使 EAI 测试可供乳腺癌患者使用，并为个性化乳腺癌治疗开辟新途径。要了解更多信息，请访问 www.delphi-diagnostics.com。</p>
<p>**Symmans 博士与 Delphi 有个人财务关系，这已被确定为与本研究的利益冲突，并由 MD Anderson 的利益冲突委员会进行管理。</p>
<p><strong>媒体联系人：</strong></p>
<p>Emily Granger</p>
<p>Delphi Diagnostics Inc.</p>
<p>[email protected]</p>
<p>508.341.9331</p>
<p>来源：Delphi Diagnostics Inc</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REE2MzU5OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNzA1UFJfTkVXU19VU1BSX19fX19EQTYzNTk4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REE2MzU5OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNzA1UFJfTkVXU19VU1BSX19fX19EQTYzNTk4"/></p>

CELC

美国医药设备 ETF - iShares

医疗业 ETF - Vanguard

标普生物技术 3 倍做多 - Direxion

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做空 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>德尔菲诊断公司已任命埃里克·林奎斯特（Eric Lindquist）为首席财务官，任职时间自 2026 年 4 月 1 日起生效。林奎斯特是一位经验丰富的肿瘤学和生命科学高管，他将领导公司的财务战略，以推动其乳腺癌治疗的内分泌活性指数（Endocrine Activity Index®）测试的发展。他之前的职位包括 InnoSIGN 的首席执行官和 Celcuity 的首席商务官。林奎斯特的专业知识预计将推动增长并增强乳腺癌诊断中的个性化治疗选择</p>

<p><em>Experienced oncology and life sciences executive to lead financial strategy and support the next phase of growth</em></p>
<div class="lb-trans"><p><em>经验丰富的肿瘤学和生命科学高管将领导财务战略并支持下一阶段的增长</em></p>
</div><p>For a PDF of this release, please click here</p>
<div class="lb-trans"><p>要查看此发布的 PDF，请点击这里</p>
</div><p>, /PRNewswire/ -- Delphi Diagnostics today announced the appointment of Eric Lindquist as Chief Financial Officer, effective April 1, 2026. Mr. Lindquist brings decades of leadership experience across pharmaceutical and diagnostics companies, with a strong track record in commercialization, corporate strategy, and capital formation. He joins Delphi at a pivotal time as the company advances its Endocrine Activity Index® (EAI™) test to improve treatment decision-making in breast cancer.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Delphi Diagnostics 今天宣布任命 Eric Lindquist 为首席财务官，任职于 2026 年 4 月 1 日生效。Lindquist 先生在制药和诊断公司拥有数十年的领导经验，在商业化、企业战略和资本形成方面有着良好的业绩记录。他在公司推进内分泌活性指数®（EAI™）测试以改善乳腺癌治疗决策的关键时刻加入 Delphi。</p>
</div><p>Most recently, Mr. Lindquist served as Chief Executive Officer of InnoSIGN, where he led a strategic transformation of the business and completed multiple financing rounds. Prior to InnoSIGN, he was Chief Business and Commercial Officer at Celcuity, where he led the acquisition of gedatolisib and helped advance the program into Phase III breast cancer trials.</p>
<div class="lb-trans"><p>最近，Lindquist 先生担任 InnoSIGN 的首席执行官，领导了公司的战略转型并完成了多轮融资。在加入 InnoSIGN 之前，他是 Celcuity 的首席商务和商业官，负责收购 gedatolisib，并帮助将该项目推进至 III 期乳腺癌临床试验。</p>
</div><p>Earlier in his career, Mr. Lindquist held senior leadership roles at Natera, where he played a key role in launching Signatera, a personalized molecular residual disease test tailored to each patient's unique cancer signature. He also contributed to establishing Roche as a leader in companion diagnostics through roles in business development and strategic partnerships.</p>
<div class="lb-trans"><p>在职业生涯早期，Lindquist 先生在 Natera 担任高级领导职务，发挥了关键作用，推出了 Signatera，这是一种针对每位患者独特癌症特征的个性化分子残留病检测。他还通过业务发展和战略合作伙伴关系的角色，帮助罗氏确立了在伴随诊断领域的领导地位。</p>
</div><p>&#34;Eric brings deep expertise at the intersection of oncology, diagnostics, and strategic finance,&#34; said Winz Casagrande, Chief Executive Officer of Delphi Diagnostics. &#34;His experience leading companies through critical growth milestones will be instrumental as we expand access to EAI and continue to build next-generation breast cancer diagnostics to guide personalized treatment.&#34;</p>
<div class="lb-trans"><p>“Eric 在肿瘤学、诊断和战略金融交汇处拥有深厚的专业知识，” Delphi Diagnostics 首席执行官 Winz Casagrande 说。“他在引导公司通过关键增长里程碑方面的经验，将对我们扩大 EAI 的可及性并继续构建下一代乳腺癌诊断以指导个性化治疗至关重要。”</p>
</div><p>&#34;Delphi Diagnostics is uniquely positioned to transform how treatment decisions are made in breast cancer,&#34; said Mr. Lindquist. &#34;The company's biology-driven approach with EAI has the potential to bring greater clarity to complex clinical decisions. I look forward to working with the team to execute on its strategy and drive long-term value.&#34;</p>
<div class="lb-trans"><p>“Delphi Diagnostics 在改变乳腺癌治疗决策方面具有独特的优势，” Lindquist 先生说。“公司基于生物学的 EAI 方法有潜力为复杂的临床决策带来更大的清晰度。我期待与团队合作，执行其战略并推动长期价值。”</p>
</div><p>Mr. Lindquist earned a Bachelor of Science in genetics and cell biology from the University of Minnesota and an MBA from Capella University.</p>
<div class="lb-trans"><p>Lindquist 先生获得明尼苏达大学的遗传学和细胞生物学学士学位，以及 Capella 大学的 MBA 学位。</p>
</div><p><strong>About EAI</strong> Delphi Diagnostics' Endocrine Activity Index® (EAI™) test can provide actionable information for prognosis and prediction of dose-intense taxane-based chemotherapy benefit in stage II-III, HR+ HER2- breast cancer. The EAI measures endocrine activity in a breast tumor, and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic indicator for long-term outcomes in stage II-III breast cancer patients, to be independent of other prognostic tests, as well as to be predictive for response to dose-dense chemotherapy.</p>
<div class="lb-trans"><p><strong>关于 EAI</strong> Delphi Diagnostics 的内分泌活性指数®（EAI™）测试可以为 II-III 期 HR+ HER2- 乳腺癌的预后和预测剂量强度紫杉烷化疗的益处提供可操作的信息。EAI 测量乳腺肿瘤的内分泌活性，作为预后使用时，指数分数根据分子亚型基因（RNA4）和肿瘤大小及区域淋巴结受累等临床因素进行基线预后调整。EAI 测试在多项研究中已被证明是 II-III 期乳腺癌患者长期结果的一致预后指标，独立于其他预后测试，并且能够预测对剂量密集化疗的反应。</p>
</div><p><strong>About Delphi Diagnostics</strong> Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive license from The University of Texas MD Anderson Cancer Center in Houston, TX to commercialize the Endocrine Activity Index, a technology that was developed by the laboratory of Dr. W. Fraser Symmans**. The Endocrine Activity Index (EAI) test measures endocrine activity in stage II-III, HR+HER2- breast cancer. Delphi's vision is to make the EAI test available to breast cancer patients and open new pathways for personalized breast cancer treatment. To learn more, visit www.delphi-diagnostics.com.</p>
<div class="lb-trans"><p><strong>关于 Delphi Diagnostics</strong> Delphi Diagnostics Inc. 是一家总部位于德克萨斯州的公司，专注于推进临床有效的乳腺癌治疗预后和预测测试。Delphi Diagnostics, Inc. 拥有来自德克萨斯大学 MD 安德森癌症中心的独家许可，以商业化内分泌活性指数，这项技术由 W. Fraser Symmans 博士的实验室开发。内分泌活性指数（EAI）测试测量 II-III 期 HR+HER2- 乳腺癌的内分泌活性。Delphi 的愿景是使 EAI 测试可供乳腺癌患者使用，并为个性化乳腺癌治疗开辟新途径。要了解更多信息，请访问 www.delphi-diagnostics.com。</p>
</div><p>**Dr. Symmans has a personal financial relationship with Delphi that has been identified as a conflict of interest with this research and is managed by MD Anderson's Conflict of Interest Committee.</p>
<div class="lb-trans"><p>**Symmans 博士与 Delphi 有个人财务关系，这已被确定为与本研究的利益冲突，并由 MD Anderson 的利益冲突委员会进行管理。</p>
</div><p><strong>Media Contact:</strong></p>
<div class="lb-trans"><p><strong>媒体联系人：</strong></p>
</div><p>Emily Granger</p>
<div class="lb-trans"><p>Emily Granger</p>
</div><p>Delphi Diagnostics Inc.</p>
<div class="lb-trans"><p>Delphi Diagnostics Inc.</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>508.341.9331</p>
<div class="lb-trans"><p>508.341.9331</p>
</div><p>SOURCE Delphi Diagnostics Inc</p>
<div class="lb-trans"><p>来源：Delphi Diagnostics Inc</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTE5Jk5ld3NJdGVtSWQ9REE2MzU5OCZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MTkxNzA1UFJfTkVXU19VU1BSX19fX19EQTYzNTk4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DA63598&amp;Transmission_Id=202605191705PR_NEWS_USPR_____DA63598&amp;DateId=20260519"/></p>

Delphi Diagnostics 公司任命 Eric Lindquist 为首席财务官